← Eichor
Condition: Persistent Cervical Cancer Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Persistent Cervical Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Low-dose Pembrolizumab Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical C
Phase 2 · 1 location(s) · Instituto Nacional de Cancer, Brazil · NCT06670911Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
Phase 2 · 100 location(s) · National Cancer Institute (NCI) · NCT07195734Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer
Phase 3 · 5 location(s) · Lee's Pharmaceutical Limited · NCT06459687Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer
Phase 1 · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT04754321Study of Treatment for HPV16+ ASC-US or LSIL
Phase 1 · 2 location(s) · University of Alabama at Birmingham · NCT03913117Comparison of 5-ALA Photodynamic Therapy and CO2 Laser for Treating Persistent Low-Grade Cervical Lesions With High-Risk
NA · 1 location(s) · First Affiliated Hospital of Wenzhou Medical University · NCT06052033Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer
Phase 2 · 1 location(s) · Zhongnan Hospital · NCT05817214Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gyne
Phase 2 · 1 location(s) · Peking University People's Hospital · NCT07586826A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer
Phase 2 · 2 location(s) · Yale University · NCT05838521PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemother
Phase 2/Phase 3 · 1 location(s) · N.N. Alexandrov National Cancer Centre · NCT07472153Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
Phase 2 · 2 location(s) · Dana-Farber Cancer Institute · NCT06677190BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer
Phase 2/Phase 3 · 1 location(s) · Bio-Thera Solutions · NCT06123884A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintena
Phase 3 · 155 location(s) · Merck Sharp & Dohme LLC · NCT07216703
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.